The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone
Open accessAbstract
BACKGROUND: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone has been proposed, but its efficacy and safety have not been well studied. METHODS: We conducted a multicenter, randomized, placebo-controlled trial involving 326 opiate-addicted persons who were assigned to office-based treatment with sublingual tablets consisting of buprenorphine (16 mg) in combination with naloxone (4 mg), buprenorphine alone (16 mg), or placebo given daily for four weeks. The primary outcome measures were the percentage of urine samples negative for opiates and the subjects' self-reported craving for opiates. Safety data were obtained on 461 opiate-addicted persons who participated in an open-label study of buprenorphine and naloxone (at daily doses of up to 24 mg and 6 mg, respectively) and another 11 persons who received this combination only during the trial. RESULTS: The double-blind trial was terminated early because buprenorphine and naloxone in combination and buprenorphine alone were found to have greater efficacy than placebo. The proportion of urine samples that were negative for opiates was greater in the combined-treatment and buprenorphine groups (17.8 percent and 20.7 percent, respectively) than in the placebo group (5.8 percent, P<0.001 for both comparisons); the active-treatment groups also reported less opiate craving (P<0.001 for both comparisons with placebo). Rates of adverse events were similar in the active-treatment and placebo groups. During the open-label phase, the percentage of urine samples negative for opiates ranged from 35.2 percent to 67.4 percent. Results from the open-label follow-up study indicated that the combined treatment was safe and well tolerated. CONCLUSIONS: Buprenorphine and naloxone in combination and buprenorphine alone are safe and reduce the use of opiates and the craving for opiates among opiate-addicted persons who receive these medications in an office-based setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment of OUD with B/N has been shown to be medically effective (increasing retention in treatment and decreasing use of illicit opioids) and cost-effective.3–8”
From Implementing Group Visits for Opioid Use Disorder: A Case Series (2020) · cites this paper as [5]
In the citing paper
“While participants’ demographic characteristics were similar to those reported in other U.S. and international studies of office-based buprenorphine/naloxone maintenance, our study sample is not necessarily representative of all opioid-dependent patients.13–15”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [14]
In the citing paper
“In this study, where craving was measured on a 0–100 mm VAS, mean craving more than halved, with a baseline score of 62.4 reducing to 29.8 after 4 weeks of treatment with a sublingual tablet formulation of 16 mg buprenorphine/4 mg naloxone (p < 0.0001, Figure 4 ) [(111) and unpublished data].”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [111]
In the citing paper
“phase III research reports indicate that buprenorphine maintenance is quite safe with equivalent adverse events to methadone and placebo”
From Maintenance Medication for Opiate Addiction: The Foundation of Recovery (2012) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.1992.03480200058024 · Cited by 567
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Self-citationA controlled trial of buprenorphine treatment for opioid dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.267.20.2750 · Cited by 199
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence
Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01186-2 · Cited by 183
Buprenorphine: a controlled clinical trial in the treatment of opioid dependence
Pani, P., Maremmani, I., Pirastu, R., Tagliamonte, A., & Gessa, G. L. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00140-4 · Cited by 149
Buprenorphine has potent kappa opioid receptor antagonist activity
LEANDER, J. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90112-2 · Cited by 140
Harris, D. S., Jones, R. T., Welm, S., Upton, R. A., Lin, E. T., & Mendelson, J. E. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00126-5 · Cited by 131
Nath, R. P., Upton, R. A., Everhart, E. T., Cheung, P., Shwonek, P. J., Jones, R. T., & Mendelson, J. E. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008236 · Cited by 125
Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts
Fudala, P. J., Yu, E., Macfadden, W., Boardman, C., & Chiang, C. N. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00008-8 · Cited by 119
Self-citationMendelson, J. E., Jones, R. T., Welm, S., Baggott, M. J., Fernandez, I., Melby, A. K., & Nath, R. P. (1999) · Psychopharmacology · doi:10.1007/s002130050804 · Cited by 102
Mendelson, J. E. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00057-7 · Cited by 101
Subjective and physiologie effects of intravenous buprenorphine in humans
Pickworth, W. B., Johnson, R. E., Holicky, B. A., & Cone, E. J. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.72 · Cited by 91
Practical aspects in data monitoring: A brief review
DeMets, D. L. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060706 · Cited by 89
Krook, A. L., Brørs, O., Dahlberg, J., Grouff, K., Magnus, P. M., Røysamb, E., & Waal, H. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00090.x · Cited by 81
French, M. T., Zarkin, G. A., Hubbard, R. L., & Rachal, J. V. (1993) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952999309002663 · Cited by 79
Buprenorphine and naloxone interactions in opiate-dependent volunteers*
Mendelson, J. E., Jones, R. T., Fernandez, I., Welm, S., Melby, A. K., & Baggott, M. J. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90173-3 · Cited by 79
Intravenous Buprenorphine Self-Administration by Detoxified Heroin Abusers
Comer, S. D., Collins, E. D., & Fischman, M. W. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.266 · Cited by 51
The effects of buprenorphine in buprenorphine-maintained volunteers
Strain, E. C., WALSH, S. L., Preston, K. L., Liebson, I. A., & Bigelow, G. E. (1997) · Psychopharmacology · doi:10.1007/s002130050199 · Cited by 48
Hughes, P. H., & Rieche, O. (1995) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036186 · Cited by 35
Opiates: prevalence and demographic factors
Hartnoll, R. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03733.x · Cited by 34
The Functioning of Individuals on a Drug Abuse Treatment Waiting List
Brown, B. S., Hickey, J. E., Chung, A. S., Craig, R. D., & Jaffe, J. H. (1989) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998908993407 · Cited by 34
Prior Treatment History and Its Impact on Criminal Recidivism
Merrill, J. C., Alterman, A. I., Cacciola, J., & Rutherford, M. J. (1999) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(99)00012-4 · Cited by 33
The Effect of Methadone Prescribing in a Clinic Setting on the Criminal Activity of Drug Users
Bates, M., & Pemberton, D. A. (1996) · Scottish Medical Journal · doi:10.1177/003693309604100606 · Cited by 14
Knolle, H. (1997) · Substance Use & Misuse · doi:10.3109/10826089709039382 · Cited by 13
Childress, A. R., McLellan, A. T., WOODY, G. E., & O’Brien, C. P. (1991) · PsycEXTRA Dataset · doi:10.1037/e496292006-009 · Cited by 9
Heroin use among young people is increasing in England and Wales
Harling, R. (1998) · BMJ · doi:10.1136/bmj.317.7156.431 · Cited by 7
Flagged first, then by citations
Research works printed but not linked: 2
- 2001, Fed Regist, 66, 4075
- Martin WR, 1976, J Pharmacol Exp Ther, 197, 517
Cited by
Sorted by citations
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312
The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction
Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L., Clark, T. W., & Alexander, G. C. (2015) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031914-122957 · Cited by 1,388
“Multiple well-designed randomized controlled trials provide strong evidence that buprenorphine maintenance and methadone maintenance are safe and effective treatments for opioid addiction (30, 40, 46, 49, 74, 75).”
Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy
(2017) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002235 · Cited by 674
Opioids and the treatment of chronic pain: Controversies, current status, and future directions.
Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013628 · Cited by 648
“In numerous controlled clinical trials, it has been demonstrated to be highly efficacious in reducing illicit opioid use and promoting treatment retention among opioid abusers (e.g., Johnson, Strain, & Amass, 2003; Kakko, Svanborg, Kreek, Heilig, 2003; O'Connor et al., 1998; Fudala et al., 2003).”
BackgroundConnock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T. E., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 610
Metadata
- Authors
- Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D.
- Affiliations
- Veterans Health Administration (US)
- National Institutes of Health (US)
- University of Maryland, Baltimore (US)
- Perry Point VA Medical Center (US)
- University of New Mexico (US)
- VA NY Harbor Healthcare System (US)
- Cincinnati VA Medical Center (US)
- VA West Los Angeles Medical Center (US)
- Edward Hines, Jr. VA Hospital (US)
- University of Pennsylvania (US)
- Boston University (US)
- VA Connecticut Healthcare System (US)
- San Francisco VA Medical Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 949-958
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2147528480
- Cited by
- 577
- References
- 30
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 20 · 2023: 26 · 2022: 22 · 2021: 45 · 2020: 24 · 2019: 20 · 2018: 23 · 2017: 27 · 2016: 24 · 2015: 32 · 2014: 31 · 2013: 36 · 2012: 33
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (3Y01-DA-30011-04)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, buprenorphine, naloxone, sublingual tablets, office-based treatment, opioid craving, urine drug testing, drug safety, opioid use reduction
- MeSH terms
- Administration, Sublingual, Adult, Ambulatory Care, Buprenorphine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Narcotics, Office Visits, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
